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Abstract
Basic research creates new knowledge that fuels technological advances. However, budg-
etary concerns and escalating R&D prices are challenging organizations to show returns 
from investments in scientific research. Few attempts are made to analyse research that 
leads to pharmaceutical innovation. In particular, the financial contribution of public and 
private organizations to the riskiest stage of biomedical discovery has remained unclear 
and partially unexplored. This study is a first attempt to shed light on the financial support 
to basic research by public and private sectors using publications data. We conducted an 
exploratory analysis of funding acknowledgments on publications authored by the found-
ing scientists of 91 ‘drug originator’ companies in United Kingdom. The nature and distri-
bution of the support acknowledged to the research conducted before the company creation 
was analysed and the impact of publications and type of support were statistically tested. 
We found the majority of publications acknowledged public institutions, whereas, com-
mercial organisations were likely to support those with privately affiliated authors. Based 
on these findings, we discussed the need to foster collaborative research and to set adequate 
incentives for shared risks and benefits from investments in knowledge creation.
Keywords Basic research · Drug discovery · Innovation · Funding acknowledgment
Introduction
The roles of public and private sectors in the discovery and development of new drugs 
are part of a long-running debate. In the past decades, the rise of novel collaborations in 
the form of industry-academy partnerships have blurred the traditional border between 
the two sectors (Etzkowitz 2003; Leydesdorff and Etzkowitz 1996; Bozeman et al. 2013; 
Bozeman 2000). Budgetary concerns and highly priced medicines are yielding increasing 
pressure on governments and raising new questions about the rates of return from public 
spending. Moreover, the argument that public sector is responsible for a large share of drug 
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development, have fuelled proposals to recoup profits from government funded drugs and 
to avoid tax payers to pay twice: first with taxes for publicly funded research, and then 
through monopoly of prices or restricted access (Sampat and Lichtenberg 2011).
The extent of public sector involvement in basic scientific research is recognized under 
the major role played by governmental funding agencies which affect the cognitive devel-
opment of science and ultimately the economic growth and competitiveness (Kearnes 
and Wienroth 2009). However, the relation between funding input and research outputs 
is difficult to map due to the number of funding sources and the variety of collaborative 
relationships.
To probe collaboration patterns, the use of publication data has been prominently 
focused on authorship, as an indicator of scientific productivity, and citations as a meas-
ure of impact (Abramo et al. 2009). More recently, however, the study of the acknowledg-
ments section of published literatures has taken part to so-called “reward triangle” and it 
is gaining ground as a source of data (Costas and van Leeuwen 2012; Cronin and Weaver 
1995). In particular, acknowledgments of financial support are of prominent importance as 
they indicate the source of funding or economic support which made possible the research 
and the publication. Moreover, acknowledgments have the potential to map the funding 
inputs without the need to gain direct access to data via funders or researchers individually 
(Rigby 2011; Grassano et al. 2017). Accordingly, the study of acknowledgment can also be 
of interest to highlight research policy purposes (Álvarez-Bornstein et al. 2017; Paul-Hus 
et al. 2016).
Given the aforementioned potentials for using publications data, in this study we seek 
to improve our understanding on the financial aspects underlying the basic research which 
led to the discovery of pharmaceuticals. In particular, we explore the scientific production 
of scientists involved in the creation of biotechnology companies in United Kingdom (UK) 
and which originated a drug development project. Our objective is to identify the nature of 
the support acknowledged by the publications authored by the founders of such enterprises. 
We seek to shed light on the financial contribution of the public and private organizations 
to the science which anticipated the company creation. Doing so, we contribute to high-
light some the financial levers which characterize the earliest and riskiest stage of pharma-
ceutical innovation.
The remainder of this paper is organised as follows. First, we present the conceptual 
motivation behind this study which we use to formulate a set of research questions. Next, 
we describe the study design and the methodology we applied to conduct our analysis. We 
subsequently present the results of our study and we discuss the main policy implications.
Previous literature and objectives
Since the biotech revolution, much has changed in the paradigm by which biomedical 
research and development (R&D) are conducted and theorized. The linear model of inno-
vation is one of the first conceptual frameworks that was developed to understand the rela-
tion between science, technology and their application to the economy (Godin 2006). This 
approach defines innovation as causal process that leads from basic to applied research 
and development ending with production and diffusion (Godin 2006). Consistently with 
the literature that followed (Bush 2001) seminal work, much basic biomedical research is 
conducted in academic/non-profit institutions and is funded by the public sector (Zycher 
et  al. 2010). Conversely, the bulk of applied and development science that concerns the 
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translation of the research findings into products or processes is funded mostly by the pri-
vate sector. Public basic research is characterized by a high degree of uncertainty in both 
its scientific maturity and its potential market applicability (Toole 2007). Therefore, the 
private sector has inadequate incentives to invest in basic research (Galkina Cleary et al. 
2018; Arrow 1978).
In the last decades, many criticisms concerning the linearity of the model have been 
raised and authors have claimed the inclusion of the dynamic interactions between aca-
demic and commercial sectors (Cockburn and Henderson 1996, 1998). Since the enact-
ment of the Bayh–Dole Act in the USA in 1980, there has been a substantial rise in the 
commercialization of science and other forms of university technology transfer (Siegel and 
Wright 2015). Universities have broadened the traditional mission of educating students 
to include the patenting and commercialization of research discoveries (Bok 2009). As a 
result, multiple channels and processes of knowledge interaction have been established 
between universities and industry which have been featured in the growing literature on 
university–industry relations (Bekkers and Freitas 2008; Bercovitz and Feldman 2006; 
Bercovitz et al. 2001).
In this context, an increasing number of university scientists started for-profit companies 
to develop their scientific breakthroughs (Etzkowitz 1983; Shane and Khurana 2003; Stuart 
and Ding 2006). In particular, academic scientists have been of critical importance for the 
emergence of the biotechnology industry. Mansfield (1991) pointed out that the pharma-
ceutical industry had the highest percentage of new products based on academic research. 
Many start-ups have been either founded by scientists or heavily rely on work of public sci-
ence (Zucker et al. 1998; McMillan et al. 2000; Audretsch and Stephan 1996). Stuart and 
Ding (2006) estimate that half of all biotechnology firms have been founded by university 
scientists, most of whom maintained academic appointments post-founding. Azoulay et al. 
(2007) found that 38% of the members of a random sample of 3800 U.S.-based, academic 
life scientists had, at some point in their careers, co-authored one or more papers with sci-
entists working in the private-sector.
Past research has employed publications data to study company innovative perfor-
mances. For example, using bibliographic information of researchers affiliated with 190 
UK-based biotechnology firms, Jong and Slavova (2014) demonstrated that firms adopting 
open science strategies were more prominent in the R&D landscape with benefits related 
to the development of radical products innovations. Some empirical studies on scientific 
human capital have demonstrated the varying performance impact of a mix of scientists 
in terms of their orientation towards publishing and patenting (Baba et  al. 2009; Stokes 
2011; Subramanian et al. 2013; Zucker et al. 2002). For these reasons, published studies by 
founding scientists contain a rich source of information which can be used to probe prob-
ing collaboration patterns, interdisciplinary linkages and other research spill overs (Wang 
and Shapira 2015). This is confirmed by Sternitzke (2010) who reported that each drug is 
accompanied by, on average, about 19 journal publications and 23 additional patents.
In the past literature, some attempts to make use of publication data were made either 
through case studies or by studies which used grant proposals, CV or performance report 
as sources for funding information (Stuart and Ding 2006; Heinze et  al. 2007). The 
acknowledgment field of publications has been used by a growing number of bibliometric 
studies. Until recent times, it was very difficult to carry out analyses on acknowledgments 
since this information was not available in bibliographic databases. However, since 2008, 
Web of Science (WoS) started including funding acknowledgment data and this opened 
up new possibilities for investigations. Some studies analysed the acknowledgment sec-
tions by disciplines or countries (Díaz-Faes and Bordons 2014; Wang and Shapira 2015; 
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Costas and van Leeuwen 2012). These highlighted the acknowledgment appeared more 
frequent in Anglo-American journals and in the so-called ‘hard sciences’ such as chemis-
try and psychology (Cronin et al. 2004). Other contributions measured the role of funded 
articles as an indicator of research quality (Gillett 1991; Costas and van Leeuwen 2012; 
Zhao 2010). Also, partnerships between the public and private sectors in multiple discipli-
nary areas have been studied using funding acknowledgement section of Spanish articles 
(Morillo 2016) founding that 79% was financed by the public and 18% in combination with 
private. The accuracy and completeness of the extraction process adopted by the extant lit-
erature have been the object of some recent contribution which also questioned and tested 
the robustness of the bibliographical databases reporting funding information (Rigby 2011; 
Grassano et al. 2017).
Yet, despite the potentials and the magnitude of publications as a source of data, the 
existing body of literature have rarely employed these into the analysis of the funding of 
pharmaceutical innovation. Based on the previous research, this paper is a first attempt to 
analyse the nature and the scope of the financial contribution acknowledged by the litera-
ture which lead to biopharmaceutical discoveries. To do so, we chose to analyse the fund-
ing acknowledgements (FA) in scientific publications authored by the founders of biop-
harmaceutical companies before the incorporation. Our focus is, therefore, the basic and 
applied research that is undertaken primarily for the advancement of scientific knowledge, 
with or without a specific practical application in view (Godin 2006). The main objectives 
addressed in this article are the following:
• To explore the nature of the financial support acknowledged in the publications by sci-
entists involved in the foundation of biotechnology companies.
• To highlight the distribution of funding organizations across countries and disciplines.
• To analyse the extent to which funding information have higher impact in terms of cita-
tions.
Moreover, based on the results of the proposed objectives, we aim to critically assess 
the position of public and private sector towards the funding and of the earliest stage of 
pharmaceutical innovation and discuss potential research policy implications.
Methods
Sample
To construct our sample, we identified 91 UK-based biotechnology firms founded between 
1996 and 2016, which originated at least one drug development project1 and received 
venture capital (VC) support according to the GlobalData Pharma Intelligence Centre’s 
database. We assumed that investments from VC represented a promising stage at which 
discoveries made in basic research may conduct and after which there might be further 
investments in development research.
1 Drug originator is when the drug is “conceptualized, discovered and initially developed and the intel-
lectual rights originate”; Active is when the developmental status or the product has been updated in 
the last 2 years, if in clinical development, or 4 years if the drug was in a preclinical development stage 
(GlobalData PlC).
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Further, we collected the biographical information of the founding scientists (full name, 
role, previous affiliation). To do so, we accessed Beaurhurst database that contains key 
information on high-growth companies that have secured equity fundraising in UK. When 
founders’ or primary scientists’ personal details were not reported, we conducted a web 
search of companies’ websites. For each company, multiple identities were selected and 
ranked according to their role. Specifically we gave more relevance to the scientists or 
those individuals that, accordingly to the information provided, were involved in the iden-
tification of the company science and its foundation (see “Appendix” for ranking criteria). 
The collection was conducted by two independent researchers, results have been compared 
afterword; any disagreement and risk of bias were solved through a discussion between the 
authors.
Data collection
A literature search was conducted using two search queries on different bibliographic 
databases.
First (method 1), we aimed to capture the most relevant publications by the founding 
scientists before the company creation. Accordingly, using Thomson Reuter’s Web of Sci-
ence (WoS) database, we collected the ten most cited articles published by the company 
founder before the year of the incorporation.
Method 1, search query author: “name of founding scientist”_ FILTER < (year of com-
pany foundation)
A second research query (method 2) was made associating the founders’ identity with 
the information regarding the products in the company pipeline. Details of the companies’ 
pipelines were downloaded from GlobalData database. Specifically, we looked at com-
pounds at the most advanced stage in development in each company pipeline. Next, we 
collected information on: (a) the disease or condition for which the drug is or is seeking 
approval (therapy area); (b) the structural, biological, chemical and/or pharmaceutical fea-
tures of the drug (molecule type); (c) the specific effect on the indication or symptoms that 
are intended to treat (mechanism of action).
Accordingly we downloaded the first publication appearing on Google Scholar for each 
of the included founding scientists. Scholar is recognized as one of the few academic search 
engines that combines several approaches in a single algorithm as a result of weighing the 
full text, the author, the publication in which the articles appears and how often the piece 
has been cited in other scholarly literature (Beel and Gipp 2009). This approach allowed 
the identification of the most relevant article per author according to the company science.
Method 2, search query “Mechanism of action “AND/OR” molecule type “AND/OR 
“therapy area” AND author: “name of scientific founder(s)”_ FILTER < (year of company 
foundation)
As a result of the two collecting strategies we aimed to include the most influential 
publications in the founders’ backgrounds (method 1) including the research made in the 
area that was then carried on within the enterprise as the base for the drug development 
(method 2).
Overall, we collected only articles written in English and published in peer-reviewed 
scientific journals. Meeting abstracts, commentaries and reviews were excluded. This two-
steps procedure yielded 714 results (620 with method 1 and 94 using method 2). Dupli-
cates originating from the two research methods (77 publications, 11%) were removed.
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Data analysis
Data cleansing was required to extract and harmonize the information contained in our 
set of publications. A first problem concerned the standardisation and disambiguation of 
author names. This arises when several authors share the same name, but also one author 
expresses his/her name in different ways. As pointed out by D’Angelo et al. (2011), manual 
inspection to disambiguate authors can be very effective for small population of scientists 
and data integration from external sources can be very helpful to ease the task. In our work, 
we used the information collected about the founders’ background from companies’ web-
sites to make an efficient use of the “article group” option provided by WoS.
Secondly, our sample was checked to identify funding information contained in the 
acknowledgement section of each article. Due to the reduced size of our sample, we opted 
for extracting, coding and interpreting funding data in addition to WoS manually. Accord-
ingly to Grassano et al. (2017), when there was no clear way to detect the financial nature 
of the support, we adopted a conservative approach and the acknowledged organisation 
was not included in the list of funders. Also, as the intention of our work was to highlight 
the financial contribution supporting the research, we included only funding data that were 
explicitly reported to the founder or acknowledged to the study, with the exclusion of all 
funding provided explicitly to other authors. Once the relevant funding information for a 
given publication were identified, we extracted the full name of the organisation and added 
the code of the country where this was located and labelled according to the scope (pub-
lic, private). Governmental bodies, charities and non-profit organisations were grouped 
as ‘public’, whereas private foundations held by commercial organisations were included 
under ‘private’ (Sussex et al. 2016; Viergever and Hendriks 2016). A thesaurus of the vari-
ous names and acronyms of funding agencies was created.
Thirdly, affiliation analysis was conducted following the approach applied by Hottenrott 
and Lawson (2017). Specifically, each author on the selected publications was attributed 
one or more institution based on the [C1] address field in WoS. All addresses were coded 
by institution type and assigned to a unique code. This was conducted semi-manually, 
meaning that a search algorithm containing word elements such as “univ”, “hosp”, “ltd” 
was undertaken using Excel, and these were marketed as universities, hospitals or compa-
nies respectively. The retrieved institutions were finally coded as belonging to the higher 
education sector (HEI),2 public or semi-governmental research institutes (PRO), private 
companies (PRIV).
The bibliometric analysis of the acknowledgement section as well as authors affiliations 
was performed in Excel. The Statistical Package for the Social Sciences (SPSS, version 
24.0 for Windows) and STATA were used to perform statistical analysis and test relations 
in our dataset. Figure 1 illustrates the study design, inclusion criteria and data collection 
strategy.
2 The majority of hospitals were university teaching hospitals and thus assigned to HEI (Viergever and 
Hendriks 2016).
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Results
A total of 637 publications, made between 1970 and 2015 and authored by 141 found-
ers of 91 biotechnology companies was included in our study. Funding data addressed 
to the founder/scientist or generically acknowledged to the study was disclosed in 403 
(63%) articles (Fig. 2).
The support from public institutions was reported in 329 (82%) publications whereas 
that from the industry or a combination of private and public organisations (“mix”) was 
found in 28 (7%) and 46 (11%) respectively. Authors were affiliated to the higher educa-
tion sector (HEI) in 72% of our sample, 14% to public or semi-governmental research 
institutes (PRO) and 10% to private companies (PRIV); 3% showed multiple affiliations 
(Fig. 3).
Table 1 illustrates the number of publications by type of funder and authors’ affiliation. 
When the publications were privately financed, authors were likely to be affiliated with pri-
vate organisations (52% vs 6% of publicly financed). A Fisher’s exact test of independence 
was performed and a significant relation between type of funding and author affiliation was 
found (p < .001). Overall, these results suggest that the distribution of funding data between 
Fig. 1  Study design
Fig. 2  Descriptive results
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affiliations is not casual and authors belonging to universities or to private corporations are 
more likely to attract public or private funding respectively (p < .001).
The study also demonstrates as a myriad of different organizations are involved in the 
funding of biomedical research that leads to the creation of biotechnology enterprises 
in UK. As such, 261 different funders (206 public, 55 private) were individuated. Major 
funders, defined as those appearing in at least 10 publications, appeared in 70% of our 
sample showing that the majority of biomedical research was funded by a small number of 
organisations. Among public funders, the Wellcome Trust, Medical Research Council and 
the National Institute of Health (NIH) were the most acknowledged together with Cancer 
Research UK. The studies in our sample were supported by 77 public institutions based 
in UK that compared in 256 publications (63%). Also the contribution of 59 US funding 
organisations was acknowledged (24%) together with that of organisations from 22 differ-
ent nationalities.
Funding acknowledgements also enabled the exploration of the extent to which funders 
are jointly disclosed in publications. In Fig. 4c we examine the co-occurrence of the ten 
major public funders. The analysis revealed that public funders most frequently jointly 
acknowledged were the Medical Research Council together with the Wellcome Trust or 
Cancer Research UK. Moreover, it is worth noting that not in a small proportion (22%), 
funding organisations were the same as the author affiliations and this value could be 
higher if we included all other authors’ affiliation in the check in addition to founders.
The WoS category classification enabled to compare the content of the studies with 
the reported funding organisation and to analyse the topics that public and private funders 
mostly support. The areas with most publications were biochemistry, oncology and science 
and technology. Figure 5a, b profile public and private funders in terms of research domain 
Fig. 3  Number of publications 
by type of funding a and authors 
affiliation b 
Table 1  Funding to publications, affiliations
HEI higher education institutions, PRO public or semi-governmental research institutes, PRIV private com-
panies; multiple affiliations: HEI, PRO, PRIV or HEI, PRO, or HEI, PRIV
Affiliation Public funding (%) Private funding (%) Mix (%) Total (%)
HEI 251 (76%) 14 (48%) 28 (61%) 292 (72%)
PRO 47 (14%) – 8 (17%) 55 (14%)
PRIV 17 (6%) 15 (52%) 10 (22%) 42 (10%)
Multiple 14 (4%) – – 14 (4%)
Total 329 29 46 403
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relative to the number of publications containing funding data. All major funders sup-
port was primarily focused on biochemistry and molecular biology. The Wellcome Trust 
together with the Medical Research Council showed a focus on science and technology 
and immunology. Cell biology was mostly investigated by Cancer Research UK that also 
showed a pronounced attention towards scientific production in oncology.
Further bibliometric indicators were used to gain a deeper understanding of how the 
interaction between public and private sectors take place within the production of scien-
tific knowledge that leads primary scientists to the creation of biotechnology companies. 
Assuming the informal sense that the first and last author positions are generally perceived 
as the ‘key’ positions on a paper, the analysis demonstrated that when authors were pub-
licly affiliated they were more often reported as first or last authors (80%) than private 
(72%). Overall, founders/scientists appeared first or last in byline position in 57% of our 
sample demonstrating a substantial contribution to the published work.
The impact of publications as measured by the number of citations per year was also 
assessed by applying non-parametric tests. Specifically, a Mann–Whitney U test showed 
that the number of citations per year was greater for publications with funding acknowl-
edgements than for the articles that did not disclosed any funding to the author or the study 
(p < .001). On the other hand, a Kruskal–Wallis H test (p = .148) indicated that the distri-
bution of citations per year was not statistically different across publications that received 
public funding compared to private or a mix of both sectors.
Discussion
The contribution of public and private entities to the early stages of pharmaceutical inno-
vation was the object of this paper. We highlighted the public sector plays a key role in 
supporting the riskiest stage of pharmaceutical innovation that is when basic, blue-sky 
Fig. 4  Top-10 public a and private funders b, co-occurrence matrix c and scope of funders d 
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research is conducted with no practical or economical application in view. The work found 
that when financial acknowledgments are disclosed, the number of citations is higher and 
therefore the broader the impact of the publication. As a consequence, we may derive the 
basic research, if conducted with the support by public or private organisation has better 
chances to be the ground for future innovations.
The topic has been investigated through a bottom-up approach taking in analysis the 
publications made by leading scientists figuring as the founders of 91 biotechnology com-
panies headquartered in UK. The discovery of innovative pharmaceuticals was explored 
assuming the production of scientific knowledge made before the incorporation to play 
a key role in the identification of the potentials for business. Discoveries made in basic 
research are significant for the process that leads to innovation. Specifically, the technol-
ogy or knowledge transfer defined as the “movement of know-how, technical knowledge or 
technology from one organizational setting to another”(Bozeman 2000), plays an increas-
ingly important role in stimulating economic development (Siegel et al. 2007). In this con-
text, it has been recognized the research support from government or industry could play 
as catalyst for enabling the innovation process. However, despite the growing emphasis 
Fig. 5  Research areas supported by public a, private or mix b, top-4 major funders c 
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on formalizing the interaction that take place between the higher educational system and 
industry as a vehicle to enhance innovation, the financial aspects related to this phenom-
enon were partially unexplored. As such, we analysed the type of support provided to the 
studies upon which we assumed the authors, once identified the potential of the results 
achieved, have started a commercial business. Contrarily we did not aim to assess or map 
the support given to biomedical research overall. Doing so, the current study sheds light on 
some financial aspects related to the discovery of pharmaceuticals.
Specifically, here we demonstrate the public sector plays a fundamental role in the 
financing of biopharmaceutical discoveries and so the risks associated. Using bibliographic 
information as a proxy, we evidenced the major role of the public sector as reported in the 
acknowledgments sections and through the affiliation of most of the authors. Surprisingly, 
the study found a tight relation between the type of support provided to publications and 
authors’ affiliation. In particular, support from private sector was almost 4 times higher 
when the founders were already privately affiliated and lower (− 38%) when these, before 
starting their own company, were belonging to public or non-profit organisations. This was 
also evidenced for those studies financed by public institutions in which, however, the rela-
tion was weaker. Also, we demonstrated that the impact of publications that acknowledged 
financial support either by the public, private or a mix of both sector was higher in terms 
of annual citations. Contrarily, the type of funding did not seem to influence the number of 
yearly citations. Furthermore, we have examined the extent to which different organisations 
are acknowledged as funders of scientific publications. As a result of our investigation, we 
found a scientific landscape populated by a large number of different institutions. The dis-
tribution among publications was highly skewed meaning that few organisations financed 
the majority (70%) of the sample. Moreover, it is worth to notice that the support given by 
public institutions was more focused on broader areas of investigation such as biochemis-
try, cell biology whereas private organisations were contributing to more applied topics 
such as oncology, immunology and chemistry.
Furthermore, the application of bibliometric analysis to publication data have shown 
potentials to inform policy making on research funding. Here, the retrieved publication 
were used to profile the research portfolios of major public funders. As a result, the number 
of studies in oncology published with the support of Cancer Research UK (CRUK) were 
three times those of other institutions and constituted 20% of CRUK portfolio. Also, a spe-
cific focus on neurosciences and neurology was found in publications that disclosed the 
Wellcome Trust as supporting institution. In addition, as a result of the manual coding of 
the retrieved literature, the study measured the precision of WoS in reporting the informa-
tion contained in the acknowledgement section. Consistently with the previous literature 
on this topic, we found that WoS did not report funding data for 20 publications (3%) for 
which our manual check evidenced financial support (false negatives).
In this study, we provide evidence whilst fully aware of the complexity of attributing a 
single conceptual framework to this topic and the limitations related to the use of biblio-
metric techniques in this field (Reichert and Milne 2002; Cockburn and Henderson 1996). 
A first critical aspect is associated with the manual coding of acknowledgements paratexts 
required to gain the appropriate understanding of the funding information to authors. Cer-
tainty the inclusion of the funding text [FU] in WoS since 2008 has enabled the analysis of 
acknowledgement section as the “third edge” of the reward triangle in bibliometric studies 
together with authorships and citations (Costas and van Leeuwen 2012).
However, the incompleteness of data provided by WoS and the lack of precision as 
highlighted by Grassano et  al. (2017), have partially limited the use of this source. In 
addition, as said, our investigation was focused solely on authors that we identified as 
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the founder of the biotechnology companies. Hence, all funding information attributed to 
other authors were due to be excluded and from this we opted for a manual coding of the 
acknowledgement sections. Furthermore there were cases in which acknowledged informa-
tion were not reported as “financial support” or “funding” but simply “supported by” and 
these were interpreted as financial as well. Consequently to that, the number of financed 
studies included in the study may be overestimated. Another limitation is represented 
by the way the identities of authors and founders have been identified and matched. The 
inclusion, despite it was made through a double-blind process conducted by two independ-
ent researchers, involved judgments and was subject to the reliability of available data. 
Precisely, we relied on the information contained in the accessed databases and compa-
nies’ websites to determine whether the name of any of the present or past employer was 
reported as the founder or the leading scientist. Other names, of other people possibly 
involved in the creation of such enterprises may have been omitted and thus not included 
in the analysis. Also, when retrieving publications from the online databases, a number of 
homonymies were found and therefore limitations in associating names with titles were 
due to the required process of disambiguation.
In conclusion, although the study covers an extensive period of time, the recent boost in 
public–private efforts, such as the Innovative Medicine Initiative (IMI) at European level, 
may not be fully evidenced in our data. The IMI is a public–private partnership between 
the European Union and the European Federation of Pharmaceutical Industries which have 
produced more than four thousand publications involving collaboration between research-
ers across different sectors, institutions and countries (Laverty and Meulien 2019). Our 
study does however extend the extant literature on academic founders by focusing on scien-
tific founders of biotechnology companies. By including different career backgrounds, our 
study demonstrates that company founders act as boundary-spanning ‘gatekeepers’ who 
facilitate access to socially embedded knowledge (Gittelman and Kogut 2003).
Future research may seek to clarify drivers of collaborative research by taking into 
account multiple processes of knowledge transfer (Fabiano et al. 2020). Research efforts 
are also encouraged to keep track of the funding given to applied research, for example by 
including publications made after the company foundation.
Conclusions
In this study, we traced the relationship between knowledge and innovation by taking a 
bottom up approach to identify the origin of an idea. Rather than observing research budg-
ets top-down, we focused our analysis on scientists who published and started a company. 
By looking into this highly specific field of knowledge production, our results confirm the 
critical role played by non-profit research institutions in the financing of innovation.
Given the scale and the complexity of the challenges health systems are facing, the 
results of our study support the thesis that further polarization may occur if collaborative 
initiatives at research level are not encouraged. Collaboration at pre-competitive stage is a 
key aspect required to accelerate the flow of knowledge between university and industry. 
Therefore, we welcome policy initiatives and research efforts bringing multidisciplinary 
and multi-stakeholders together.
Furthermore, given the key role governments play a in both promoting innovation and 
in the generation of new market opportunities, risks and benefits need to be shared amongst 
actors at industrial level (Mazzucato 2011). From a policy perspective, the outcome of our 
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research advocates a shift towards a mission-oriented approach in which governments set 
the direction of innovation towards public needs. To support this, the pricing structure of 
pharmaceuticals should reflect the dual role taxpayers play in funding early innovation and 
as final users.
Funding This research did not receive any specific Grant from funding agencies in the public, commercial, 
or not-for-profit sectors.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, 
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other third party material in this article 
are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly 
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Appendix
See Table 2.
Table 2  Ranking criteria adopted 
to identify key employers Ranking Role
1 Co-Founder/inventor of the innovation
1 Scientific Founder
1 Scientific co-founder
1 Founder/Chief Scientist
1 Scientific Founder and Advisor
1 Founding Scientist and Head of department
2 Founder
2 Founder, CEO
2 Founder, CSO
2 Founder, Executive Director
2 Inventor/manager
3 Co-Founder
3 Co-Founder and Chief Medical Officer
3 Co-Founder and Chief Scientific Officer
3 Co-Founder, Chairman
3 Co-Founder, Chief Scientific Officer
3 Co-Founder, Managing Director
4 Non-Executive Director, Co-founder
4 Development
4 Director of medical, chemistry department
4 Chief Technology Officer
4 Chairman and Director of Drug
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